Senseonics Holdings, Inc.
Moat Score — Senseonics Holdings, Inc.
Total Moat Score
10 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Senseonics holds roughly 500 issued and pending patents covering its implantable sensor chemistry and holds FDA Class III premarket approval (PMA) for Eversense, the only long-term implantable CGM on the market. That regulatory and IP position is real but narrower than the broader patent estates of Dexcom and Abbott. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | The company outsources all manufacturing to contract manufacturers and relies on a single key supplier for certain raw materials. At its small production scale it has no cost advantage versus Dexcom or Abbott, who manufacture at vastly greater volume. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Eversense's long duration supports a premium positioning, but pricing and payer negotiation run through its commercial partner Ascensia, and reimbursement in the CGM category is largely payer-driven rather than company-set, limiting Senseonics' direct pricing leverage. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in implantable CGM: one patient's use of Eversense does not make the product more valuable to another patient, clinician, or payer. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once implanted, a patient has some practical inertia to stay with Eversense until the sensor's end of life (up to 365 days with Eversense 365), and clinicians who are trained and equipped for insertion/removal have some switching friction. But at each renewal cycle patients can freely move to a skin-worn competitor, so lock-in is moderate at best. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Implantable CGM is a small, specialized niche that Dexcom, Abbott, and Medtronic have largely chosen not to contest with their own implant, leaving Senseonics a protected but genuinely tiny addressable segment rather than a scale-driven moat. |